A new report by the Institute of Cancer Research (ICR) looks at the cancer drug pipeline, including trends in innovation and access between 2000 and 2016.
The European Medicines Agency, according to the report, licensed 97 cancer drugs across 177 indications between 2000-2016. The rate of authorizations between 2000-2008 and 2009-2016 reportedly doubled from 7.5 per year to 14.6 per year, respectively.
Despite the increasing number of cancer treatments being authorized by the EMA, concerns remain about the number of therapies being approved for various cancer types.
“For many types of cancer, such as skin, breast, prostate and haematological cancers, we have seen dramatic advances in treatment over the last decade as cancer patients reap the rewards from progress in research,” the report states. ” … Patients with other tumour types are not benefiting from such exciting progress, with many cancers seeing few or no drug authorisations over the time period.”